Cost Analysis of Conversion Total Knee Arthroplasty: A Multi-Institutional Database Study

Steven Denyer, Carlo Eikani¹, Daniel Bujnowski², Hassan Farooq³, Nicholas Michael Brown

¹Loyola University Medical Center, ²Loyola School of Medicine, ³Loyola University Health System

INTRODUCTION: Total knee arthroplasty (TKA) after prior knee surgery, also known as conversion total knee arthroplasty (convTKA), has been associated with higher complications, resource utilizations, and associated costs. The increased surgical complexity and burden of convTKA may not be reflected by the relative value units (RVU) assigned under the current coding guidelines. The purpose of this study was to compare the RVUs of TKA and convTKA and to calculate the RVU per minute to account for work effort.

METHODS: The American College of Surgeons National Surgical Quality Improvement Project (NSQIP) database was analyzed for the years 2006-2020. CPT codes (27447) and (27447 and 20680) were used to identify patients who underwent primary and convTKA, respectively. After a 1:1 propensity score matching, 1,600 cases were assigned to each cohort. The RVU-to-dollar conversion factor was obtained from the US Centers for Medicare and Medicaid Services (CMS). RVU dollar valuations were calculated per operative time. Univariate analysis on outcome variables were performed utilizing the matched groups. Complication rates were compared using a multivariate logistic regression model controlling for baseline characteristics.

RESULTS: The mean operating time for TKA was 97.8 minutes with a respective RVU per minute of 0.25, while the mean operating time for convTKA was 124.3 minutes with an RVU per minute of 0.19 (p=<0.0001). Using the conversion factor of \$36.04 per RVU, this translated to \$8.84 per minute for TKA compared to \$6.90 per minute for convTKA. ConvTKA was associated with increased overall complications (10.9% vs. 7.6%, p=<0.0001), higher blood transfusion (6.6% vs. 3.7%, p=<0.0001), reoperation (2.3% vs. 1.1%, p=<0.0001), and readmission rates (3.7% vs. 2.8%, p=<0.0431).

DISCUSSION AND CONCLUSION: The current billing guidelines lead to lower compensation for convTKA, despite its increased complexity. The longer operation times, higher complication rates, and increased resource utilization may disincentivize providers from performing this operation. CPT code revaluation is warranted to reflect the time and effort associated with this procedure.

Baseline characteristics for patients undergoing primary TKA versus Conversion TKA. Univariate analysis before and after								ore and after	244-1	Table 3									Table 4												
properate access	TEA CathOld P-Velar					P-W	stor	Work KYU Comparison Retween TKA and ConTKA on matched schorts.					Incidence of Adverse Events for Patients Undergoing Conv/TKA Versus TKA.									Odds of Bost-surgical	Complications	as Galated to Datis	et Demoerachin	and Comorbidity	w When Corr	nariaa			
	No.	Faste (%)	No.	Rate (N)	No.	Rate (%)	efore propensity matching	After propensity matching		TKA ==1600	ConvTKA #1900	Pilake		Unma	tched	CotwTXA Unmatched		ρ. Value	TKA Matched	8	atched	p. Value	ConvTKA to TKA.								
Total Patients	332,800	200	391,200	100	1,600	100			Work RVU	21.18 (\$763.73)	21.34 (\$365.5)	0.0919																			
58X Female	101100 611		241 245	61.8	755	47.4	10001	115EW	Operative time	97.8 +/- 35.77	124.3 +/-47.49	<0.0001		No.	Rate	No.	Rate		No. Rate	No.	Rate			Adverse to	ALL A	Crivanase	MUSIKINISE				
Male	150,294	38.5	141.455	38.2	841	52.6			RVU per minute	0.25 +/- 0.09	0.13 +/- 0.07	<0.0001			(%)		(%)		(%)		(%)			Ma	Decourt Hill	0.104.00	O441 Batin	95%	P.Molan.		
Unknown	2	0	2	0					Dollar per minute	8.84	6.9 +/- 2.47	+0.0001	Any adverse	29,538	7.6	174	20.9	<.0001	104 6.5	174	20.88	<.0001	New exercises of union	100	T COULD IN	1.16595					
GIVI in kg/m2							0.0005	0.1932					event		L								event	121	3.78	0.0072	1.579	11-2.3	0.0146		
<10	115,939	\$5.5	334,526	85.5	1,413	89.3			Com/D/A, comercine total losse with	SSI	SSI 2,668 0.68 20 Wound 835 0.2 8	1.25	0.006	10 0.63	20	125	0.0666		30	1.10		1.000	00000								
340	56,861	14.5	56,674	14.5	187	11.7			per /WU convension factor of \$36.02	Wound		8	0.5	0.0134	2 0.13	8	0.5	0.1088				0.09999	1.645		4.1000						
App							<.0001	0.1979					dehiscence										Wound dehiscence		0.5	0.1055	1.005	0.97-9.3	0.0561		
CO years	13,894	15	14,039	15	1.314	15.3				Septils 751 0.2 5 0.3 0.2486 1 0.06 5 0.31 0									1 0.06	5	0.31	0.1021	Blood Transfusion	105	6.63	0.0002	1.715	1.2-2.4	0.001		
200 anors	20.341	22	28 200	7.2	41	26													0.1408	Return to the OR	37	2.31	0.0021	2.383	1.3-4.2	0.0028					
DM							<.0001	0.6992					PRODUIN	1,100	0.0	-	0.2	0.0413	0 0		0.19	0.2498	Bendmission	50	1.92	0.0004	2 099	11.11	0.0013		
Mo	121.354	81.8	819.924	81.8	1.90	25.3							Intubation	569	0.1	0	0	0.1832	0 0	0	0										
Yes	71,445	18.2	71,226	18.2	220	13.8							issues																		
HTN							<.0001	0.3371				PE	1,862	0.5	2	0.1	0.0416	5 0.31	2	0.13	0.4526	OR, odds totic: Any <u>portravullation</u> event, superficial or deep surgical site infection, debiscence, sepsis, preumonia, intubation issues,									
No	135,024	34.4	134,282	34.3	742	46.4				007	3.052	0.9		05	0 2022	9 05	0	0.5		tract infections ML manage	artial infantion	in or, or reserves	cre, pariorary en	contract, or i, only re-	in or por indexes, o	it analy					
Yes	257,776	65.6	256,918	65.7	858	53.6																									
OHF							0.6891	1					Blood	14,554	3.7	106	6.6	<.0001	60 3.75	106	6.63	0.0002									
No	\$91,548	99.7	383,354	99.7	1,594	99.6							Transfusion																		
res	1,454	0.3	7,049			9.4							Acute Renal	205	0.1	0	•	1	2 0.13	0	0	0.4998									
Ma	333138	00.8	100.013		1000	00.8	0.3582	03/40					Failure																		
Yes	572	0.2	653	0.2	4	01							utti	3,005	0.8	10	0.6	0.5119	3 0.19	10	0.63	0.0916									
0070								0.7325					M	713	0.2	5	0.3	0.2236	2 0.13	5	0.31	0.2563									
No	379,161	96.5	377,602	96.5	1,559	97.A	0.05						Contra	367	0.1	1.1	0.2	0.1161	1 0.05		0.10	0.0348									
Yes	13,639	3.5	13,598	15	41	2.6							Cardiac	28/	0.1		0.2	0.1161	1 0.06		0.19	0.6248									
bleeding disorders							0.528	0.7259					Return to the	4,413	1.1	37	2.3	<.0001	15 0.94	37	2.31	0.0021									
No	354,134	97.8	382,573	97.8	1,561	97.6							OR																		
Yes	8,600	2.2	8,627	2.2	30	2.4							Readmission	11,063	2.8	59	3.7	0.0431	27 1.79	59	3.92	0.0004									
Smoking							<.0001	0.6235					Death	271	01	2	01	0 3053	1 0.06	2	0.13	0.6248									
No	361,196	92	359,846	92	1,350	84.4														-											
ATA Classification	31,004	•	31,304		104	15.0	- 0001	A 1804																							
AGA CLESHICEDON	335 270	48.7	164 413	40.7	011	19.4	0001	0.1230					ConvTKA, conve	raion total k	nee arthrop	lasty; TKA,	total knee	arthroplast	c SSI, surgical si	te infection	r; PE, pultr	onary									
1014	200,010	50.5	156,755	50.3	112	41.4							embolism; DVT,	deep vein ti	womboski; U	JTI, urinary	rtract infer	ction; Mi, m	yocardial infarct	ion.											
Steroid use							0.3901	0.8374																							
No	328,973	66.S	277.423	96.5	1.550	96.9																									
Yes	13,827	3.5	13,777	2.5	50	3.1																									
Ganelist converse	tatal knee ard	vopiaray, 1	TCA, Eural knew	arthropia	7/ 688, 50	dy mass index; I	OM, diabetes; HTN, h	ypersession; DHF,																							